Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis | Arthritis Research & Therapy | Full Text

Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis | Arthritis Research & Therapy | Full Text

Arthritis Research & Therapy

Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis

• Jayne Moxey,
• Molla Huq,
• Susanna Proudman,
• Joanne Sahhar,
• Gene-Siew Ngian,
• Jenny Walker,
• Gemma Strickland,
• Michelle Wilson,
• Laura Ross,
• Gabor Major,
• Janet Roddy,
• Wendy Stevens and
• Mandana NikpourEmail author

Arthritis Research & Therapy201921:57

https://doi.org/10.1186/s13075-019-1839-5

©  The Author(s). 2019

• Received: 16 November 2018
• Accepted: 1 February 2019
• Published: 14 February 2019

Abstract

Background

Up to 12% of patients with systemic sclerosis (SSc) have anti-neutrophil cytoplasmic antibodies (ANCA). However, the majority of these patients do not manifest ANCA-associated vasculitis (AAV) and the significance of ANCA in these patients is unclear. The aim of this study is to determine the prevalence of ANCA in a well-characterised SSc cohort and to examine the association between ANCA and SSc clinical characteristics, other autoantibodies, treatments and mortality.

Methods

Clinical data were obtained from 5 centres in the Australian Scleroderma Cohort Study (ASCS). ANCA positive was defined as the presence of any one or combination of cytoplasmic ANCA (c-ANCA), perinuclear ANCA (p-ANCA), atypical ANCA, anti-myeloperoxidase (anti-MPO) or anti-proteinase-3 (anti-PR3). Associations of demographic and clinical features with ANCA were investigated by logistic or linear regression. Survival analysis was performed using Kaplan-Meyer curves and Cox regression models.

Results

Of 1303 patients, 116 (8.9%) were ANCA positive. Anti-PR3 was more common than anti-MPO (13.8% and 11.2% of ANCA-positive patients, respectively). Only 3 ANCA-positive patients had AAV. Anti-Scl-70 was more common in ANCA positive vs ANCA negative (25% vs 12.8%, p < 0.001), anti-MPO positive vs anti-MPO negative (38.5% vs 13.6%, p = 0.006) and anti-PR3 positive vs anti-PR3 negative patients (44.4% vs 13.4%, p < 0.001). A higher prevalence of interstitial lung disease (ILD) was found in the ANCA positive (44.8% vs 21.8%, p < 0.001) and the anti-PR3 positive groups (50.0% vs 23.4%, p = 0.009). In multivariable analysis, ANCA-positive status remained associated with ILD after adjusting for anti-Scl-70 antibodies. Pulmonary embolism (PE) was more common in ANCA-positive patients (8.6% vs 3.0%, p = 0.002) and anti-PR3-positive patients (16.7% vs 3.3%, p = 0.022). ANCA-positive status remained associated with PE in a multivariable analysis adjusting for anti-phospholipid antibodies. Kaplan-Meier analysis revealed increased mortality in ANCA-positive patients (p = 0.006). In Cox regression analysis, ANCA was associated with increased mortality, after adjusting for age and sex.

Conclusions

ANCA is associated with increased prevalence of ILD and PE in SSc. ANCA should be tested in SSc, as it identifies individuals with worse prognosis who require close monitoring for adverse outcomes.

Keywords

• Anti-neutrophil cytoplasmic antibodies (ANCA)
• Systemic sclerosis (SSc)
• ANCA-associated vasculitis
• Myeloperoxidase (MPO)
• Proteinase-3 (PR3)